Dr Mani Mohindru has been appointed by Curis, a drug development company focusing on cancer treatments, to serve as its new vice president of corporate strategy and investor relations.
A seasoned biotechnology professional, Dr Mohindru will provide support in developing the corporate strategy, investor relations and corporate communications at the Boston-based, NASDAQ-listed firm.
Commenting on the hire in a company press release, Curis chief business and financial officer Mike Gray says: ‘Dr Mohindru brings to Curis a strong and unique understanding of cancer drug markets and development strategies due to her wealth of experience in the analysis of the biotechnology sector. Mani’s diverse set of industry knowledge, professional networks and experience will be an important addition to our team as we seek to advance our pipeline of novel oncology drug candidates for patients and work to create long-term shareholder value.’
Prior to joining Curis, Dr Mohindru spent several years as a Wall Street equity research analyst, including roles at ThinkEquity, Credit Suisse Securities and UBS Securities. She also worked as a healthcare industry consultant at Axon Healthcare Partners and SAI Healthcare, and as a managing director in healthcare investment banking at Capstone Investments.
She holds a PhD in neurosciences from Northwestern University, a bachelor’s degree in human biology, and a master’s degree in biotechnology from the All India Institute of Medical Sciences in New Delhi, India.
Revealing her excitement at her new position, Dr Mohindru says: ‘I am excited to join the Curis team as the company continues to advance its proprietary cancer drug candidates CUDC-907 and CUDC-427 in clinical trials, and to work with our partners Genentech and Debiopharm on Erivedge® and Debio 0932. Given these achievements, I believe Curis is well positioned to leverage its expertise in developing cancer therapeutics and become a leading innovator of targeted oncology drug candidates.’
